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Abstract
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Here we review a novel class of delivery vehicles based on pH-sensitive, moderately polar
membrane peptides, which we call pH (Low) Insertion Peptides (pHLIPs), that target cells located
in the acidic environment found in many diseased tissues, including tumors. SpecificAcidity
targeting by pHLIPs is achieved as a result of helix formation and transmembrane insertion. In
contrast to the earlier technologies based on cell-penetrating peptides, pHLIPs act as monomeric
membrane-inserting peptides that translocate one terminus across a membrane into the cytoplasm,
while the other terminus remains in the extracellular space, locating the peptide in the membrane
lipid bilayer. Therefore,This geometry gives pHLIP has a dual delivery capability: it can tether
cargo molecules or nanoparticles to the surfaces of cells in diseased tissues and/or it can move a
cell-impermeable cargo molecule across the membrane into the cytoplasm. The source of energy
for moving polar molecules attached to pHLIP through the hydrophobic layer of a membrane
bilayer is the membrane-associated folding of the polypeptide. A drop in pH leads to the
protonation of negatively charged residues (Asp or Glu), which enhances peptide hydrophobicity,
increasing the affinity of the peptide for the lipid bilayer and triggering peptide folding and
subsequent membrane insertion. The process is accompanied by the release of energy that can be
utilized to move cell-impermeable cargo across a membrane. That the mechanism is now
understood, and that targeting of tumors in mice has been shown, suggest a number of future
applications of the pHLIP technology in the diagnosis and treatment of disease.
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Acidity; membrane-associate folding; translocation across membrane; imaging; drug delivery;
cancer
Medical science constantly seeks to improve the diagnosis and treatment of disease, and new
delivery technologies may contribute in several ways, including:
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Targeted therapy: selective delivery of therapeutic and imaging agents to diseased
tissue, thereby increasing the effective concentration of these agents and reducing their
accumulation in healthy tissue.
Improved routeroutes of drug administration: encapsulation of therapeutic agents to
improve pharmacokinetic properties of a drug.
Locally activated therapy: activation of a targeted therapeutic agent by external
effectors.
Multi-functionality: simultaneous targeted delivery of a therapeutic agent and an
imaging probe to monitor drug distribution.

Author Manuscript

New approaches to drug design: use of a new class of therapeutic agents: cellimpermeable molecules that would be are translocated into cells only in diseased tissue
while not affecting healthy cells.
A therapy that would employemploying any or all of these concepts might exhibit much
higher efficacy and/or significantly reducereduced side effects. Such improvements are
especially importantneeded for cancer treatment, since the majority of anti-cancer drugs are
poisons that damage normal cells. In the following, we place special emphasis on cancer, but
it should be recognized that other diseased tissues might be treated using the strategies we
discuss.

Nanosized carriers for improved route of drug administration and multifunctionality
Author Manuscript
Author Manuscript

Various nanosized drug-delivery vehicles, such as organic, metallic or semiconductor
nanoparticles, liposomes, micelles, viral particles, polymers and dendrimers are designed to
address the limitations of conventional drug delivery systems, including low aqueous
solubility, poor bioavailability and low therapeutic indices stemming from insufficient drug
concentration at disease sites (Davis et al., 2008, Gindy and Prud’homme, 2009). The
principle of drug encapsulation is extremely important, since it may create an opportunity to
use many amphiphilic or polar drugs that have established activities but cannot be used since
they do not passively cross a cell membrane. Another advantage is multi-functionality: both
therapeutic and imaging agents can be loaded at the same time in one nanoparticle to
monitor the amount and location of a therapeutic administration, using clinical imaging
methods. Among nanosized drug carriers are self assembling lipid-containing systems such
as liposomes and micelles, which deliver molecules trapped inside or within their
hydrophobic phospholipid bilayer (Semalty et al., 2009). Viruses have also been envisaged
as nanoparticle vectors suitable for drug delivery, vaccines, and gene therapy due to their
regular geometries, well characterized surface properties, and nanoscale dimensions (Aghi
and Martuza, 2005, Everts and van der Poel, 2005, Lin and Nemunaitis, 2004). At the same
time, despite extensive investigation of dozens of viral vectors for cancer treatment, and
promising results in clinical trials, the FDA has not approved any virus-based therapeutics,
because of toxicities widely reported in gene therapy. Various polymer molecules are
traditionally employed as drug delivery systems (Moghimi, 2006). Formulations using
dendrimers, hyper-branched synthetic macromolecules with controllable sizes and shapes,
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for drug delivery may have advantages over traditional polymeric systems (Samad et al.,
2009, Tekade et al., 2009).

Local activation therapy

Author Manuscript
Author Manuscript

A recentlyAn evolving strategy is to target an inactive entity to a tissue, and then activate it
with a signal, reducing incidental damage to a patient below the level attainable by either a
targeting strategy or an activating signal alone. Such synergistic binary approaches might
use activation by electromagnetic radiation, ultrasound, neutrons or other effectors
(Kankaanranta et al., 2007, O’Connor et al., 2009, Pisarev et al., 2007, Schroeder et al.,
2009). These are promising directions for the development of therapeutic approaches with
restricted side effects. Natotechnology has led to the fabrication of inorganic nanomaterials,
including nanocrystals, nanotubes and nanowires, with physical properties that appear
promising for biological and medical applications. For example, carbon nanotubes,
nanoshells and gold nanorods have attracted attention due to their strong absorbance in the
near infrared (NIR) window and release of energy in the form of heat, which can induce
irreversible local damage to the cells in a tumor (Hainfeld et al., 2004, Morris et al., 2006,
O’Connell et al., 2002). Hyperthermia can also be stimulated by using magnetic field
fluctuations to heat magnetic-nanoparticles (Duguet et al., 2006, Ito et al., 2005, Latorre and
Rinaldi, 2009). Neutron capture therapy based on the irradiation of boron-10 or gadolinium
clusters with thermal neutrons, generating short range high linear energy ionizing particles,
provides a means to deliver radiation locally at the cellular level (Kankaanranta et al., 2007,
Mitin et al., 2009, Pisarev et al., 2007). Another approach is to use NIR light to activate light
sensitive molecules to produce free radicals, which can destroy cancer cells (photodynamic
therapy) (O’Connor et al., 2009, Palumbo, 2007). Interaction of gold nanoparticles with keV
radiation of an appropriate energy can generate Auger and photo-electrons inducing death of
the cells in the vicinity of a gold nanoparticle (Hainfeld et al., 2004). Light or ultrasound can
also be used to enhance drug release at a disease site (Liapi and Geschwind, 2007, Schroeder
et al., 2009). Thus, there are many strategies that might be used if selective delivery to a
diseased tissue can be accomplished. However, finding the means to accomplish the
selective delivery to tumors or other tissues still remains a challenging problem, as discussed
below.
Disease-specific delivery coupled with local activation would allow i) accumulating and,
therefore, increasing the effective concentration of therapeutic or diagnostic agents in a
diseased area and so ii) reducing the side effects associated with treatment by reducing the
targeting of normal cells. Adding the dimension of local activation would further improve
the protection of normal tissue.

Author Manuscript

Cancer biomarkers and traditional targeting strategies
A great deal of effort has been devoted to the design and development of tumor selective
agents to improve visualization and treatment of cancerous tissue. Traditionally, receptors
and enzymes overexpressed in cancer cells are considered to be cancer biomarkers, serving
as indicators of the change in physiologic state during a the disease process (Hanke et al.,
2004, Janssens et al., 2004, Srinivas et al., 2001), and so there has been a focus on peptides
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and antibody fragments directed toward cell surface receptors (Freimark et al., 2007,
Goldsmith, 1997). Monoclonal antibodies were initially thought to be the most promising
candidates for specific targeting strategies; however, because of problems associated with
their specificity and high molecular weight, clinically successful developments have proven
difficult (Blättler and Chari, 2001). Only over the last few years has advanced antibody
engineering technology enabled therapeutic concepts based on antibodies and conjugates
thereof to successfully enter clinical practice (Carter, 2001, Payne, 2003). Antibodies and
their fragments have been used to map the expression or overexpression of tumor-related
proteins, such as prostate-specific membrane antigen (Polascik et al., 1999), human
epidermal growth factor receptor-2 (HER2) (Moasser, 2007); carcinoembryonic antigen (Lu
et al., 2007, Muxi et al., 1999)), TAG-72 (Muxi et al., 1999), Ep-CAM (de Bono et al.,
2004) and others. However, a number of complications still vex antibody applications, such
as purity, immunogenicity, slow diffusion in tissues, plasma clearance, and production
difficulties (Blättler and Chari, 2001).
An attractive, related direction is the development of low molecular weight peptides for
rapid tumor targeting. In contrast to antibodies, peptides can be easily synthesized, modified
and stabilized to obtain optimized pharmacokinetic parameters (Lister-James et al., 1997,
Signore et al., 2001). Usually they are not immunogenic and can have high receptor affinity.
The most developed and widely accepted are somatastatin analogs introduced to visualize
various somatostatin receptor-positive tumors (Buchsbaum, 2004, Krenning et al., 1999). A
number of other peptides targeting various receptors expressed in cancer cells have recently
been tested for tumor diagnosis as well (Ma et al., 2007, Signore et al., 2001).

Tumor acidosis
Author Manuscript
Author Manuscript

The most important limitation of specific cancer cell receptor targeting is the heterogeneity
of human cancers (Jeffrey et al., 2005). Recent studies of gene expression in cancer cells
indicate that a number of genes are up- and down-regulated, and that cells in a tumor are
heterogeneous. It is therefore problematic to rely on any single tumor biomarker even for
one type of cancer (Bild et al., 2006). Using tumor acidity may be an alternative, since it is
well established that salient features of the microenvironment of solid tumors include
hypoxia and extracellular acidity (Gatenby and Gillies, 2008, Griffiths, 1991). These factors
contribute to the selection of the cancerous phenotype, and also to the progression from
benign to malignant tumors. Acidosis is associated with tumor development both at very
early and at advanced stages (Gillies et al., 1994, Raghunand et al., 1999a)1999b). Rapidly
proliferating cancer cells become partially anaerobic, leading to the elevation of glycolysis
in response to hypoxia (Pasteur effect) (Krebs, 1972). Hypoxia and acidity are partly a result
of the chaotic and heterogeneous microvasculature structure of solid tumors, where the
oxygen concentration decreases with distance from a capillary (Gillies et al., 1999,
Schornack and Gillies, 2003). Hypoxia and low blood supply are involved in cancer
progression, but they are not the only mechanism responsible for the development of an
acidic environment within solid tumors. A hallmark of malignant cancers is an elevated
glucose uptake even under normal oxygen conditions, known as “aerobic glycolysis” or the
Warburg effect (Warburg et al., 1927). Cells exhibiting a Warburg effect catabolize glucose
at a high rate (Gillies et al., 2008, Newell et al., 1993).
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The consequence of glycolytic metabolism in any tissue is the formation of H+, which must
be removed from the cell if the internal milieu is to maintain its normal pH, because many
cellular processes have a narrow pH optimum. Four major types of intracellular pH (pHi)
regulatory mechanisms have been identified in tumor cells: Na+/H+ exchangers, bicarbonate
transporters, proton-lactate symporters and proton pumps (Martinez-Zaguilan et al., 1993,
Robertson et al., 2004, Sennoune et al., 2004). These transmembrane proteins are ion pumps
or ion exchangers that pump protons across the plasma membrane from the cytoplasm to the
opposite site of the membrane, the extracellular space or the lumen of various organelles. A
consequence of the activity of ion pumps is an enhanced pH gradient across the plasma
membrane of cancer cells in comparison with normal cells, and a lower pH in the
extracellular milieu (Becelli et al., 2007, Gatenby and Gillies, 2004, Raghunand et al.,
1999a, Tannock and Rotin, 1989).

Author Manuscript
Author Manuscript

Usually, exposure to an acidic environment results in cell death, however cancer cells adapt
through resistance to apoptosis and up-regulation of membrane ion channels in order to
maintain intracellular pH in the range of normality (Gatenby and Gillies, 2004). Indeed, the
unfavorable environment may favor tumor cell survival in acidic conditions via selection of
cells that are resistant to acid-induced cell toxicity and hypoxia-induced, p53-dependent
apoptosis (Gatenby et al., 2007, Graeber et al., 1996, Park et al., 1999, Williams et al.,
1999), and promote invasiveness by killing normal tissue cells. Malignant tumor cells not
only survive better in acidic environments, but they also demonstrate phagocytotic and
cannibalistic behavior (Fais, 2007, Lugini et al., 2006). Extracellular acidification promotes
cancer invasion and metastasis by increased secretion and activation of proteases, matrix
metalloproteinases, bone morphogenetic protein-1-type metalloproteinases, tissue serine
proteases, and adamalysin-related membrane proteases (Bhujwalla et al., 2002, MartinezZaguilan et al., 1996, Rofstad et al., 2006). Enhanced mutation rates (Bindra and Glazer,
2005, Yuan and Glazer, 1998), chromosomal instability (Morita et al., 1991), and
spontaneous transformation (LeBoeuf et al., 1990) are associated with acidity. Hypoxia and
acidity also cause resistance to radiotherapies and chemotherapies (Raghunand and Gillies,
2001, Raghunand et al., 1999b1999c, Vaupel et al., 1989), and promote the expression of the
human multi-drug-resistance protein (Wei and Roepe, 1994).
Tumor acidity might be an alternative to specific molecular biomarkers for tumor targeting
and detection and may also be useful for monitoring therapy outcomes. Recently it has been
shown that the level of extracellular pH is related to the overall survival of canines with
spontaneous sarcomas. Thus, the pH was predictive of a clinical outcome (Lora-Michiels et
al., 2006). The advantages of targeting acidity include its generality and the absence of
tumor heterogeneity issues.

Author Manuscript

The need for hydrophobicity has been a constraint on drugs
If the target of a therapeutic is cytoplasmic, the selective delivery of therapeutics to a tumor
is not enough to improve treatment; the strategy must also enable the agent to cross the
hydrophobic barrier of a cell membrane and release its payload to act inside cells. The two
major mechanisms for the translocation of molecules and nanoparticles across the membrane
are passive diffusion and endocytosis, although the latter still relies on permeation of the
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endosomal membrane (Andresen et al., 2005, Kim, 2007). Neither is specific for cancer
cells, so each would promote translocation of therapeutics across the membranes of cells in
both diseased and healthy tissues. In conventional drug design and discovery the Lipinski
rules of five are widely used to guide molecular designs. The rules postulate that a
successful drug should be hydrophobic and small in order to traverse membranes and reach
cytoplasmic targets (e.g. the logarithm of the octanol-water partition coefficient LogPo/w is
-0.4 to +5.6 and the MW is 160 to 480 g.mol-1) (Lipinski et al., 2001). Drugs designed in
this way will indiscriminately enter all cells they encounter, and are also likely to be
substrates for efflux pumps that reduce their efficacy. It is important to note that the majority
of inhibitors found for biological targets located inside a cell are molecules (in most cases,
peptides) that cannot cross a membrane (Sun et al., 2008, Tsutsumi and Neckers, 2007,
Wang et al., 2000). Another large class of cell-impermeable functional molecules comprises
gene regulation agents such as DNA, siRNA, and PNA (peptide nucleic acid) (Elayadi and
Corey, 2001, Knudsen and Nielsen, 1997). Gene-targeted therapies might lead to a
revolution in cancer therapeutics; however, the delivery of these agents, involving passage
through the cell membrane, appears to be a general problem (Nielsen, 2005).

Author Manuscript

Cell-penetrating peptides are used as one approach to the delivery of liposomes,
nanoparticles, adenoviruses, and a variety of biological molecules into cells (Munoz-Morris
et al., 2007, Patel et al., 2007, Thoren et al., 2000). Among these peptides are TAT (peptide
derived from the trans-activating transcriptional activator (TAT) protein), antennapedia,
arginine-rich peptides and others. The mechanisms of entry are still under discussion (Vives
et al., 2003) but it is most likely they enter cell via the endocytic pathway and act
cooperatively. When taken up by endocytosis, molecules or nanoparticles are trapped in the
lysosome compartment and need to be released into the cytoplasm. To induce this process, a
pH-sensitive polymer coating has been developed (Ganta et al., 2008). Usually, the
polymers contain multiple carboxyl groups, which become protonated in an acidic
endosome (pH 5.0) and change their properties to break through the membrane.

Membrane peptides as a novel class of delivery agents

Author Manuscript

The folding and insertion into membrane of constitutive membrane proteins is facilitated by
complex molecular machines in vivo, including the translocon that places most
transmembrane helices across the bilayer (Osborne et al., 2005, Van den Berg et al., 2004,
White and von Heijne, 2004). At the same time, non-constitutive membrane proteins, such
as toxins, antimicrobial peptides, C-tail proteins insert themselves into a lipid bilayer
without assistance. It has been found that moderately polar transmembrane domains with
sequences of up to 85 residues can translocate themselves into membranes in a translocondefective yeast strain, in contrast to more hydrophobic sequences that cannot (Brambillasca
et al., 2006, Brambillasca et al., 2005). Further, there is a class of synthetic peptides that fold
and insert when they interact with a lipid bilayer (Holt and Killian, 2009, Wimley and
White, 2000). Because the spontaneous insertion and folding of a peptide into a lipid bilayer
should seek the free energy minimum, an insertion event is accompanied by a release of
energy (Engelman et al., 2003). Therefore, it is reasonable to suppose that the energy might
be used to translocate cell-impermeable cargo molecules across a cellular membrane. It
follows that moderately hydrophobic peptides might be considered as the basis for a novel
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class of delivery agents. However, several key properties must be preserved for practical
use, including aqueous solubility and lack of toxicity.

pH (Low) Insertion Peptide: pHLIP

Author Manuscript

Attempts have been made to design synthetic peptides that are soluble in aqueous solution,
and that spontaneously and selectively insert into a membrane (Wimley and White, 2000).
The only significant success to date remains the discovery of pHLIP, named from: pH (Low)
Insertion Peptide (Figure 1). pHLIP is a water-soluble polypeptide derived from the
bacteriorhodopsin C helix, which was found to insert across a membrane to form a stable
transmembrane alpha helix (Hunt et al., 1997). Peptide folding and membrane insertion are
driven by a drop of pH from neutral or high (>7.4) to slightly acidic (7.0-6.5 and less) pHs.
The apparent pK of insertion was found to be 6.0 (Hunt et al., 1997, Reshetnyak et al.,
2008). pHLIP is a monomer in each of its three major states: unstructured and soluble in
water (state I) at neutral pH, unstructured and bound to the surface of a membrane at neutral
pH (state II), and inserted across the membrane as an α-helix at low pH (state III) (Figure 2).

Toxicity

Author Manuscript

Toxicity is one of the most critical issues in the selection of any delivery agent. For
example, the use of pore-forming membrane peptides as delivery agents is complicated by
the toxicity associated with the formation of pores in cellular membranes in vivo (Shai,
1999). By contrast, the interaction of pHLIP with liposomes and cellular membranes at both
neutral and low pHs does not lead to membrane leakage (Reshetnyak et al., 2007, Zoonens
et al., 2008), and no cellular toxicity was seen over a range of peptide concentrations
(Andreev et al., 2007). Also, mice receiving a high dose (about 5 mg/kg) of peptide did not
show any obvious adverse effects within two months after intravenous peptide
administration (Andreev et al., 2009). Despite these encouraging observations, a systematic
toxicity study is needed.

Selectivity of targeting

Author Manuscript

The pH-dependent interaction of pHLIP with membranes allows selectivity in the targeting
of acidic diseased tissue. As noted above, acidity and hypoxia are considered as universal
cancer biomarkers, and pHLIP is used as an acidity-targeting probe (Andreev et al., 2009,
Vavere et al., 2009). Besides cancer, many other pathological states, such as inflammation,
ischemia, stroke, arthritis and others are characterized by acidity in the extracellular space,
which may broaden the potential applications of pHLIP (Holzer, 2009, Kellum et al., 2004,
Xiong et al., 2008). In vivo fluorescence imaging in mice and rats demonstrates that pHLIP
can target acidic tissues, such as kidneys, tumors of various sizes and origins, and the site of
experimentally induced inflammatory arthritis (Andreev et al., 2009). In addition to
fluorescence imaging, PET (positron emission tomography) imaging of the acidic
environment in human prostate tumors was performed using 64Cu-DOTA conjugated to
pHLIP (Vavere et al., 2009). PET studies demonstrated that the construct avidly
accumulated in LNCaP and PC-3 tumors and that tumor uptake correlates with the
differences in the bulk extracellular pH (pHe) measured by MR spectroscopy. Feeding

Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 8

Author Manuscript

animals with bicarbonated water, which increases tissue pH (Raghunand et al.,
1999a)1999b), results in a reduction of tumor targeting by pHLIP (Vavere et al., 2009).

Molecular mechanism of pH-dependent membrane insertion of pHLIP

Author Manuscript
Author Manuscript

The putative transmembrane (TM) part of pHLIP peptide contains two Asp residues (see
Figure 1). At neutral pH these charged residues enhance peptide solubility and serve as
anchors keeping the peptide at the surface of membrane, thereby preventing pHLIP
partitioning into the hydrophobic membrane bilayer (Andreev et al., 2009, Musial-Siwek et
al., 2009, Musial-Siwek et al., 2010). A reduction of pH induces protonation of Asp
residues, and as a result, the overall hydrophobicity of the peptide increases, enhancing the
affinity of the peptide for the lipid bilayer core and triggering peptide folding and insertion.
The replacement of the key Asp residues in by Lys, Ala or Asn leads to the loss of peptide
of pH-dependent membrane insertion, as measured in liposomes, red blood cells and
confirmed by in vivo fluorescence imaging (Andreev et al., 2009, Musial-Siwek et al.,
2009)2010). The K-pHLIP peptide, where the two Asp residues in the putative
transmembrane region are replaced with Lys residues, does not demonstrate tumor targeting
(Andreev et al., 2009, Musial-Siwek et al., 2009)2010). The Ala substitutions give a peptide
that aggregates in solution, while the Lys and Asn substitutions give peptides that are too
polar to insert either at neutral or low pH. The replacement of one of the Asp residues in the
TM part of the peptide by a Glu residue results in a shift of pH of membrane insertion from
6.0 to 6.5 (Andreev et al., 2009, Musial-Siwek et al., 2009)2010). Replacement of both Asp
residues by Glu results in enhancement of peptide aggregation and formation of elements of
secondary structure on the bilayer surface at neutral pH. There are experimental data, as well
as theoretical calculations are indicating that pK of protonation/deprotonation of various
amino acids located at border of lipid bilayer or inside membrane could be significantly
altered (Balashov, 2000, Ghosh et al., 2009, Ladokhin and White, 2004, Yoo and Cui,
2008). Therefore it is not surprising to observe that the apparent pK for Asp residues in
pHLIP is 6.0 and could be altered to higher or lower values.
Data obtained on model systems (liposomes), cultured cells and mice allow us to conclude
that the mechanism of membrane entry of pHLIP is not mediated by endocytosis,
interactions with cell receptors or pore formation (Andreev et al., 2009, Reshetnyak et al.,
2006, Reshetnyak et al., 2007); rather, the mechanism is simply the formation of a helix
across the lipid bilayer, triggered by the increase of peptide hydrophobicity due to the
protonation of negatively charged residues induced by low pH.

Solubility and stability of pHLIP in blood
Author Manuscript

Poor solubility due to aggregation is a typical property of membrane peptides, which has
complicated studies and applications. pHLIP, as any membrane peptide, also has a tendency
to aggregate, especially at high concentrations and/or low pH (Musial-Siwek et al.,
20092010, Reshetnyak et al., 2007). However, in aqueous solution at neutral pH pHLIP
exists as a monomer at concentrations less than 30 μg/mL (~7.0 μM), as studied by
fluorescence and CD spectroscopy measurements, size exclusion chromatography coupled
with “on-line” laser light scattering, ultraviolet and refractive index detection (SEC-
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LS/UV/RI) and analytical ultracentrifugation experiments (Reshetnyak et al., 2007). Our
studies indicate that, when the solubility of the peptide is compromised as a result of
mutations, the affinity of the peptide for a membrane and its overall conformational
properties can change.
The oligomeric state of the peptide on the surface of a membrane (state II) and inserted into
the lipid bilayer (state III) were evaluated by FRET performed with two different donoracceptor probes attached to the N-terminus of the peptide (Reshetnyak et al., 2007). The data
demonstrate that, at low concentrations, the peptide is monomeric in both states II and III.

Author Manuscript

Peptide interactions with proteins, especially plasma proteins, and membranes determine the
pharmacokinetics of the peptide at neutral pH. pHLIP demonstrates prolonged circulation in
the blood (several hours), which is consistent with its ability to bind weakly to membrane
surfaces at neutral and high pH, preventing the rapid clearance by the kidney expected for a
small, soluble peptide (Andreev et al., 2009, Reshetnyak et al., 2008). According to our data,
pHLIP binding to membranes is mostly driven by hydrophobic interactions (Reshetnyak et
al., 2008). If the peptide sequence were made more hydrophobic, we would expect tighter
binding to red blood cells and epithelial cells and more aggregation in solution, and slower
clearance and reduced bioavailability. On the other hand, making the peptide less
hydrophobic might accelerate clearance and prevent the peptide from finding its targets.
Therefore, solubility is an important property to manage as applications in vivo are
developed.

Author Manuscript

Another important property is the stability of peptides in the blood, since proteases in the
serum can degrade peptides consisting of L-amino acids within minutes. While polypeptides
made from D-amino acids are much more stable (Hong et al., 1999), they are often
unsuitable for specific receptor binding applications as a consequence of their altered
chirality. Since the mechanism of pHLIP involves relatively nonspecific interactions with a
fluid lipid bilayer, it is not a surprise that pHLIP peptides composed of L- or D-amino acids
demonstrate the same biophysical and tumor targeting properties (Andreev et al., 2009).
This observation adds to the evidence that the pHLIP targeting does not require any specific
molecular binding event. The only conspicuous difference is that D-pHLIPs form lefthanded helices across membranes rather than the right-handed helices formed by L-pHLIPs
(Andreev et al., 2009).

Topology of membrane insertion

Author Manuscript

Is there a specific orientation of pHLIP insertion, or can either end insert? The topology of
pHLIP insertion was probed using an NBD-dithionite quenching assay (McIntyre and
Sleight, 1991), and then confirmed in experiments on cultured cells (Reshetnyak et al., 2006,
Thevenin et al., 2009). NDB and IANBD were covalently attached to the N- and the Cterminus of pHLIP peptides, respectively (Reshetnyak et al., 2006, Reshetnyak et al., 2007).
Fluorescently labeled peptides were inserted into the lipid bilayer at low pH, and changes of
in the fluorescence signal of NDB NBD were measured after quenching by dithionite, a
membrane-impermeable agent that abolishes NBD fluorescence if it contacts the dye. The
data clearly indicate that the N-terminus of pHLIP stays outside of the bilayer, while the C-
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terminus inserts across the lipid bilayer at low pH (Reshetnyak et al., 2006, Reshetnyak et
al., 2007).

Cargo translocation by pHLIP insertion

Author Manuscript

What is the source and magnitude of the insertion energy that might be used to move cargo
across a membrane? The partition of pHLIP into the outer leaflet of lipid bilayer at neutral
pH and the folding/insertion at low pH are accompanied by the release of energy
(Reshetnyak et al., 2008). Fluorescence spectroscopy, isothermal titration calorimetry and
acid titration calorimetry were used to study the interactions of pHLIP with a POPC lipid
bilayer and to calculate the transition energies between states. The Gibbs Free Energy of
binding to a POPC surface (state I - state II transition) at 37°C is about -7 kcal/mol near
neutral pH and the additional free energy of insertion and folding across a lipid bilayer at
low pH (state II - state III transition) is nearly -2 kcal/mol (Reshetnyak et al., 2008). The
energy difference between state II and state III could be used to move favor the partition of
cargo across the hydrophobic bilayer of membrane. By knowing this energy, it is possible to
estimate the polarity of cargo molecules that can be translocated across a membrane by
pHLIP: 2 kcal/mol might be enough to translocate molecules with LogPo/w ~ -1.4 [ΔG = RT lnPo/w, where RT ~0.6 kcal/mol at room temperature]. Thus, membrane-impermeable
cargo molecules with LogPw/o in range of -0.5 to -3 might be translocated (with probability
proportional to the LogPo/w) across a membrane. If the cargo is released, as in delivery to a
cell using a link that is broken in the cytoplasm, the progressive mass action will exploit
even a weakly favorable energy balance to accumulate delivered cargo in a cell.

Author Manuscript

To experimentally evaluate the range of cargo polarity that pHLIP can move across a
membrane we used an assay based on the NDB-dithionite quenching experiments described
above (Thevenin et al., 2009). NDB was attached to cyclic peptides having a range of
hydrophobicity, with calculated LogPo/w values at low pH ranging from -2.6 to -8.5. The
cyclic peptides were conjugated to a Cys residue at the C-terminus of pHLIP via an S-S
bond, and translocation was accessed by quenching of NBD fluorescence. We found that
cargo molecules with a LogPo/w of ~−2.6 and MW of ~800 are delivered into both
liposomes and cancer cells at low pH with an efficiency of about 70%, while cargo
molecules with calculated LogPo/w values of -8 could not be moved across either membrane
(Thevenin et al., 2009). These results are in good agreement with the expectation from the
thermodynamics studies.

Kinetics of pHLIP insertion into membrane
Author Manuscript

While the equilibrium thermodynamics favor binding and insertion of pHLIP, slow kinetics
could be limiting for in vivo use, since blood flow is very fast. Kinetic studies of pHLIP
folding and insertion across a POPC lipid bilayer triggered by a pH drop from 8.0 to 4.0
indicate that insertion takes 100 sec(!), with a rapid (0.1 sec) interfacial helix formation
followed by insertion to give a transmembrane helix (Andreev et al., 2010). In the case of a
pH drop to 6.0 the insertion is slower, about 300 sec (unpublished work). However, recent
data obtained on various pHLIP variants show that the process of insertion can be
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accelerated by 10-20100 times if acidic residues are removed from the C-terminus of the
peptide (unpublished work).

Dual delivery capability of pHLIP

Author Manuscript

pHLIP, in contrast to cell-penetrating peptides, stays in the cellular membrane after
insertion, translocating one end into cytoplasm and leaving the other end in the extracellular
space (Andreev et al., 2009). Therefore, the peptide possesses dual delivery capabilities: it
can tether cargo molecules to the cell surface and/or it can inject and release cellimpermeable cargo molecules into the cytoplasm (Figure 3). In the first scenario, a cargo
molecule is attached to the pHLIP N-terminus. External cargo could be of Suitable external
cargo molecules might possess a wide range of polarity and size. One of the applications can
be to deliver imaging probes to acidic tissue, where they will be stably tethered to the
surfaces of cells. Our recent data indicate that pHLIP can deliver and tether various
nanoparticles to the surface of cancer cells (unpublished data). The second delivery
capability of pHLIP is based on the conjugation of cargo molecules to the C-terminus via a
bond that is cleaved in the environment of the cytoplasm, such as a disulfide. Since the
energy released during peptide folding and insertion across a membrane is limited, and since
strongly polar molecules will reach equilibrium slowly, there is a limit on cargo polarity
(and most probably on size as well) that can be delivered across a membrane by pHLIP,
even taking into account the mass action effect discussed above. For example, we did not
succeed in the translocation of a 20 base oligonucleotide, probably because of theits highly
charged backbone (Reshetnyak et al., 2006).

pHLIP-mediated translocation of cell-impermeable functional cargos
Author Manuscript
Author Manuscript

As already discussed, pHLIP can translocate cargo molecules attached to its C-terminus.
Translocation is selective for low pH, and various types of cargo molecules attached by
disulfides can be released in the cytoplasm, including various fluorescent dyes, synthetic
cyclic peptides, toxins and peptide nucleic acids (Reshetnyak et al., 2006). We have shown
that a cell-impermeable fluorescently-labeled toxin, phalloidin-rhodamine, conjugated to the
C-terminus of pHLIP via an S-S- bond, can be moved across the membrane in a pHdependent manner (Reshetnyak et al., 2006) and unpublished work. The pH-dependent
translocation of the fluorescent phalloidin by the peptide was confirmed by fluorescence
microscopy and fluorescence activated cell sorting. If phalloidin-rhodamine enters a cell, it
binds tightly to actin filaments at nanomolar concentration (KD = 40 nM) and strongly
inhibits their depolymerization (Wehland et al., 1977). Actin filaments stained with
fluorescent phalloidin have an unmistakable filamentous pattern, distinct from the
appearance of other cellular structures, organelles or membrane staining. The phalloidin
translocated into the cytoplasm of live cells inhibits the proliferation, contractility, migration
and division of cells. A long term effect of phalloidin is the formation of multinucleated
cells, since nuclei can divide in treated cells, but the cell itself cannot. This process leads to
the formation of multiple nuclei in one cell and eventual cell death.
Another example is the translocation of a class of cell-impermeable functional cargomolecule, peptide nucleic acids (PNA), by pHLIP (Reshetnyak et al., 2006). PNAs can base
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pair specifically to target nucleic acid sequences, but lack the highly charged backbone of
biological nucleic acids, and are therefore candidates for pHLIP delivery. In vitro studies
show that PNA can inhibit both transcription and translation of genes to which it has been
targeted, which suggests use of PNA in antigene and antisense therapy (Nielsen, 2005).
However, a major obstacle has been the delivery of PNA (as well as RNA or ODN) across
membranes into cells. We have demonstrated the ability of pHLIP to translocate a
fluorescence-labeled 12 base PNA into cells (Reshetnyak et al., 2006). Treatment of cells
with PNA-rhodamine alone did not give fluorescent staining of cells at pH 6.5 or 7.4, but
fluorescence was observed in cells when the PNA was linked to the C-terminus of pHLIP
via a disulfide and added at pH 6.5. We verified that the labeled cells were alive by using the
dead cell marker SYTOX-Green. In more recent in vivo studies we find that pHLIP can
deliver an18-base PNA (MW 4.7 kDa) to a mouse tumor, translocate PNA across
membranes, and activate luciferase expression in a result of splicing correction (unpublished
work).

pHLIP represents pHLIPs are a new class of delivery agents

Author Manuscript
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In summary, we would like to outline the general features that define the pHLIP class of
polypeptides. To date, we have studied more than 20 different variants of the parent pHLIP
sequence given in Figure 1. The sequence is presented as having three main blocks. The
middle part is a moderately polar sequence that contains protonatable residues, and is the
environment-sensitive, membrane inserting part of the peptide. Recent studies show that the
transmembrane helix might be as short as 15 residues (London and Shahidullah, 2009),
therefore we assume that the membrane-inserting sequences might consist of ~15 to 25
amino acids. The other two blocks are the two flanking sequences. The role of the flanking
sequences is mostly to modulate the peptide solubility, but might also include functional
motifs; for example, protease cleavage or receptor binding sequences, or amino acids that
can undergo phosphorylation in the cytoplasm. There are several restrictions applied to the
flanking sequence that inserts across the membrane: i) it should not contain many charged
residues (especially positive charges); ii) it should not be long; iii) the speed and
cooperativity of peptide insertion into membrane will depend on the number of Asp or Glu
residues present in this sequence. On the other hand, there is no specific restriction to the
flanking sequence that stays outside of membrane other than its role in peptide solubility;
however a danger is that dramatic changes of peptide pharmacokinetics might result from
extreme variations. The membrane-inserting sequence of pHLIP does not contain Cys or Lys
residues. Any of these residues or both could be placed at the N- or C-terminus of the
peptide for the purpose of cargo conjugation to pHLIP (NHS and maleimide click chemistry
is developed very well and widely used for conjugation purposes). We are optimistic that the
pHLIP technology will have utility in a variety of medical and scientific applications.

Acknowledgments
This work was supported in part by grants from the Department of Defence BCRP CDMRP BC061356 and the
National Institutes of Health National Cancer Institute RCA125280A to OAA, RO1133890 to OAA, DME, YKR,
and GM073857 to DME. We thank all the members of the Andreev, Engelman and Reshetnyak laboratories for
their essential contributions to the pHLIP project.

Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 13

Author Manuscript

References

Author Manuscript
Author Manuscript
Author Manuscript

Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene. 2005; 24:7802–16.
[PubMed: 16299539]
Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, Engelman DM,
Reshetnyak YK. Mechanism and uses of a membrane peptide that targets tumors and other acidic
tissues in vivo. Proc Natl Acad Sci U S A. 2007; 104:7893–8. [PubMed: 17483464]
Andreev OA, Engelman DM, Reshetnyak YK. Targeting acidic diseased tissue. New technology based
on use of the pH (Low) Insertion Peptide (pHLIP). Chemistry Today. 2009; 27:10–13.
Andreev OA, Karabadzhak AG, Weerakkody D, Andreev GO, Engelman DM, Reshetnyak YK. The
pHLIP peptide inserts across a lipid bilayer as a helix, and exits by a different path. Proc Natl Acad
Sci U S A. 2010
Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and
prospects of active and tumor specific drug release. Prog Lipid Res. 2005; 44:68–97. [PubMed:
15748655]
Balashov SP. Protonation reactions and their coupling in bacteriorhodopsin. Biochim Biophys Acta.
2000; 1460:75–94. [PubMed: 10984592]
Becelli R, Renzi G, Morello R, Altieri F. Intracellular and extracellular tumor pH measurement in a
series of patients with oral cancer. J Craniofac Surg. 2007; 18:1051–4. [PubMed: 17912080]
Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. Combined vascular
and extracellular pH imaging of solid tumors. NMR Biomed. 2002; 15:114–9. [PubMed: 11870907]
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM,
Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway
signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439:353–7. [PubMed:
16273092]
Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of
microenvironment-induced mutagenesis. Mutat Res. 2005; 569:75–85. [PubMed: 15603753]
Blättler, WA.; Chari, RVJ. Drugs to Enhance the Therapeutic Potency of Anticancer Antibodies,
Antibody-Drug Conjugates as Tumor-Activated Prodrugs. Washington, DC: American Chemical
Society; 2001.
Brambillasca S, Yabal M, Makarow M, Borgese N. Unassisted translocation of large polypeptide
domains across phospholipid bilayers. J Cell Biol. 2006; 175:767–77. [PubMed: 17130291]
Brambillasca S, Yabal M, Soffientini P, Stefanovic S, Makarow M, Hegde RS, Borgese N.
Transmembrane topogenesis of a tail-anchored protein is modulated by membrane lipid
composition. EMBO J. 2005; 24:2533–42. [PubMed: 15973434]
Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene
transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med. 2004;
34:32–46. [PubMed: 14735457]
Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001; 1:118–29.
[PubMed: 11905803]
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer.
Nat Rev Drug Discov. 2008; 7:771–82. [PubMed: 18758474]
de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A,
White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF. ING-1, a monoclonal antibody
targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004; 10:7555–
65. [PubMed: 15569986]
Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in
medicine. Nanomed. 2006; 1:157–68.
Elayadi AN, Corey DR. Application of PNA and LNA oligomers to chemotherapy. Curr Opin Investig
Drugs. 2001; 2:558–61.
Engelman DM, Chen Y, Chin CN, Curran AR, Dixon AM, Dupuy AD, Lee AS, Lehnert U, Matthews
EE, Reshetnyak YK, Senes A, Popot JL. Membrane protein folding: beyond the two stage model.
FEBS Lett. 2003; 555:122–5. [PubMed: 14630331]

Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 14

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer
Gene Ther. 2005; 12:141–61. [PubMed: 15472714]
Fais S. Cannibalism: a way to feed on metastatic tumors. Cancer Lett. 2007; 258:155–64. [PubMed:
17977647]
Freimark B, Clark D, Pernasetti F, Nickel J, Myszka D, Baeuerle PA, Van Epps D. Targeting of
humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple
epitopes on denatured collagens. Mol Immunol. 2007; 44:3741–50. [PubMed: 17507095]
Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug
and gene delivery. J Control Release. 2008; 126:187–204. [PubMed: 18261822]
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4:891–
9. [PubMed: 15516961]
Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008; 8:56–
61. [PubMed: 18059462]
Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ. Cellular
adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007;
97:646–53. [PubMed: 17687336]
Ghosh N, Prat-Resina X, Gunner MR, Cui Q. Microscopic pKa analysis of Glu286 in cytochrome c
oxidase (Rhodobacter sphaeroides): toward a calibrated molecular model. Biochemistry. 2009;
48:2468–85. [PubMed: 19243111]
Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3aminopropylphosphonate. Am J Physiol. 1994; 267:C195–203. [PubMed: 8048479]
Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of
cancers. J Nucl Med. 2008; 49(Suppl 2):24S–42S. [PubMed: 18523064]
Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion
in tumors. Neoplasia. 1999; 1:197–207. [PubMed: 10935474]
Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in
cancer therapy. Expert Opin Drug Deliv. 2009; 6:865–78. [PubMed: 19637974]
Goldsmith SJ. Receptor imaging: competitive or complementary to antibody imaging? Semin Nucl
Med. 1997; 27:85–93. [PubMed: 9144853]
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated
selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379:88–91.
[PubMed: 8538748]
Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991; 64:425–7. [PubMed: 1911181]
Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in
mice. Phys. Med Biol. 2004; 49:309–315.
Hanke JH, Webster KR, Ronco LV. Protein biomarkers and drug design for cancer treatments. Eur J
Cancer Prev. 2004; 13:297–305. [PubMed: 15554558]
Holt A, Killian JA. Orientation and dynamics of transmembrane peptides: the power of simple models.
Eur Biophys J. 2009
Holzer P. Acid-sensitive ion channels and receptors. Handb Exp Pharmacol. 2009:283–332. [PubMed:
19655111]
Hong SY, Oh JE, Lee KH. Effect of D-amino acid substitution on the stability, the secondary structure,
and the activity of membrane-active peptide. Biochem Pharmacol. 1999; 58:1775–80. [PubMed:
10571252]
Hunt JF, Rath P, Rothschild KJ, Engelman DM. Spontaneous, pH-dependent membrane insertion of a
transbilayer alpha-helix. Biochemistry. 1997; 36:15177–92. [PubMed: 9398245]
Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic
nanoparticles. J Biosci Bioeng. 2005; 100:1–11. [PubMed: 16233845]
Janssens JP, Verlinden I, Gungor N, Raus J, Michiels L. Protein biomarkers for breast cancer
prevention. Eur J Cancer Prev. 2004; 13:307–17. [PubMed: 15554559]
Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast
cancer. J Natl Compr Canc Netw. 2005; 3:291–300. [PubMed: 16002001]

Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 15

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Kankaanranta L, Seppala T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M,
Uusi-Simola J, Makitie A, Seppanen M, Minn H, Kotiluoto P, Auterinen I, Savolainen S, Kouri M,
Joensuu H. Boron neutron capture therapy in the treatment of locally recurred head and neck
cancer. Int J Radiat Oncol Biol Phys. 2007; 69:475–82. [PubMed: 17689034]
Kellum JA, Song M, Li J. Science review: extracellular acidosis and the immune response: clinical and
physiologic implications. Crit Care. 2004; 8:331–6. [PubMed: 15469594]
Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics.
Nanomedicine. 2007; 3:103–10. [PubMed: 17442621]
Knudsen H, Nielsen PE. Application of peptide nucleic acid in cancer therapy. Anticancer Drugs.
1997; 8:113–8. [PubMed: 9073307]
Krebs HA. The Pasteur effect and the relations between respiration and fermentation. Essays Biochem.
1972; 8:1–34. [PubMed: 4265190]
Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH,
Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R. Radiolabelled somatostatin analogue(s) for
peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999; 10(Suppl 2):S23–9.
[PubMed: 10399029]
Ladokhin AS, White SH. Interfacial folding and membrane insertion of a designed helical peptide.
Biochemistry. 2004; 43:5782–91. [PubMed: 15134452]
Latorre M, Rinaldi C. Applications of magnetic nanoparticles in medicine: magnetic fluid
hyperthermia. P R Health Sci J. 2009; 28:227–38. [PubMed: 19715115]
LeBoeuf RA, Kerckaert GA, Aardema MJ, Gibson DP. Multistage neoplastic transformation of Syrian
hamster embryo cells cultured at pH 6.70. Cancer Res. 1990; 50:3722–9. [PubMed: 2340519]
Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J
Clin Oncol. 2007; 25:978–86. [PubMed: 17350947]
Lin E, Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther. 2004; 11:643–64. [PubMed:
15286681]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to
estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv
Rev. 2001; 46:3–26. [PubMed: 11259830]
Lister-James J, Moyer BR, Dean RT. Pharmacokinetic considerations in the development of peptidebased imaging agents. Q J Nucl Med. 1997; 41:111–8. [PubMed: 9203850]
London E, Shahidullah K. Transmembrane vs. non-transmembrane hydrophobic helix topography in
model and natural membranes. Curr Opin Struct Biol. 2009; 19:464–72. [PubMed: 19665887]
Lora-Michiels M, Yu D, Sanders L, Poulson JM, Azuma C, Case B, Vujaskovic Z, Thrall DE, Charles
HC, Dewhirst MW. Extracellular pH and P-31 magnetic resonance spectroscopic variables are
related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer
Res. 2006; 12:5733–40. [PubMed: 17020978]
Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal
cancer. Expert Opin Ther Targets. 2007; 11:235–44. [PubMed: 17227237]
Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G,
Rivoltini L, Malorni W, Fais S. Cannibalism of live lymphocytes by human metastatic but not
primary melanoma cells. Cancer Res. 2006; 66:3629–38. [PubMed: 16585188]
Ma L, Yu P, Veerendra B, Rold TL, Retzloff L, Prasanphanich A, Sieckman G, Hoffman TJ, Volkert
WA, Smith CJ. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide
conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide
receptor. Mol Imaging. 2007; 6:171–80. [PubMed: 17532883]
Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are
functionally expressed in plasma membranes of human tumor cells. Am J Physiol. 1993;
265:C1015–29. [PubMed: 8238296]
Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the
invasive behavior of human melanoma cells. Clin Exp Metastasis. 1996; 14:176–86. [PubMed:
8605731]
McIntyre JC, Sleight RG. Fluorescence assay for phospholipid membrane asymmetry. Biochemistry.
1991; 30:11819–27. [PubMed: 1751498]
Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 16

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Mitin VN, Kulakov VN, Khokhlov VF, Sheino IN, Arnopolskaya AM, Kozlovskaya NG, Zaitsev KN,
Portnov AA. Comparison of BNCT and GdNCT efficacy in treatment of canine cancer. Appl
Radiat Isot. 2009; 67:S299–301. [PubMed: 19428264]
Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene.
2007; 26:6577–92. [PubMed: 17486079]
Moghimi SM. Recent developments in polymeric nanoparticle engineering and their applications in
experimental and clinical oncology. Anticancer Agents Med Chem. 2006; 6:553–561. [PubMed:
17100563]
Morita T, Nagaki T, Fukuda I, Okumura K. Effect of pH on the activity and stability of clastogens in
the in vitro chromosomal aberration test with Chinese hamster ovary K1 cells. Mutat Res. 1991;
262:159–66. [PubMed: 1900572]
Morris KN, Weil MD, Malzbender R. Radiochromic film dosimetry of contrast-enhanced radiotherapy
(CERT). Phys Med Biol. 2006; 51:5915–25. [PubMed: 17068373]
Munoz-Morris MA, Heitz F, Divita G, Morris MC. The peptide carrier Pep-1 forms biologically
efficient nanoparticle complexes. Biochem Biophys Res Commun. 2007; 355:877–82. [PubMed:
17331466]
Musial-Siwek M, Karabadzhak A, Andreev OA, Reshetnyak YK, Engelman DM. Tuning the insertion
properties of pHLIP. Biochim Biophys Acta. 2009/2010; 1798:1041–1046. [PubMed: 19766589]
Muxi A, Pons F, Vidal-Sicart S, Setoain FJ, Herranz R, Novell F, Fernandez RM, Trias M, Setoain J.
Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72
monoclonal antibody. Nucl Med Commun. 1999; 20:123–30. [PubMed: 10088160]
Newell K, Franchi A, Pouyssegur J, Tannock I. Studies with glycolysis-deficient cells suggest that
production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci U S A. 1993;
90:1127–31. [PubMed: 8430084]
Nielsen PE. Addressing the challenges of cellular delivery and bioavailability of peptide nucleic acids
(PNA). Q Rev Biophys. 2005; 38:345–50. [PubMed: 16600055]
O’Connell MJ, Bachilo SM, Huffman CB, Moore VC, Strano MS, Haroz EH, Rialon KL, Boul PJ,
Noon WH, Kittrell C, Ma J, Hauge RH, Weisman RB, Smalley RE. Band gap fluorescence from
individual single-walled carbon nanotubes. Science. 2002; 297:593–6. [PubMed: 12142535]
O’Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology:
preclinical and clinical advances in photodynamic therapy. Photochem Photobiol. 2009; 85:1053–
74. [PubMed: 19682322]
Osborne AR, Rapoport TA, van den Berg B. Protein translocation by the Sec61/SecY channel. Annu
Rev Cell Dev Biol. 2005; 21:529–50. [PubMed: 16212506]
Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin Drug Deliv. 2007;
4:131–48. [PubMed: 17335411]
Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase
activity. Br J Cancer. 1999; 80:1892–7. [PubMed: 10471036]
Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical
perspectives. Pharm Res. 2007; 24:1977–92. [PubMed: 17443399]
Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell. 2003; 3:207–12. [PubMed:
12676579]
Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and
future. Arq Bras Endocrinol Metabol. 2007; 51:852–6. [PubMed: 17891250]
Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW.
Comparison of clinical staging algorithms and 111indium-capromab pendetide
immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma
patients. Cancer. 1999; 85:1586–92. [PubMed: 10193950]
Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, Gillies RJ.
Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma
xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol. 1999a;
57:309–12. [PubMed: 9890558]
Raghunand N, Gillies RJ. pH and chemotherapy. Novartis Found Symp. 2001; 240:199–211.
discussion 265-8. [PubMed: 11727930]
Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 17

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D,
Bhujwalla ZM, Gillies RJ. Enhancement of chemotherapy by manipulation of tumour pH. Br J
Cancer. 1999b; 80:1005–11. [PubMed: 10362108]
Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of
acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol.
1999c; 57:1047–58. [PubMed: 10796075]
Reshetnyak YK, Andreev OA, Lehnert U, Engelman DM. Translocation of molecules into cells by pHdependent insertion of a transmembrane helix. Proc Natl Acad Sci U S A. 2006; 103:6460–5.
[PubMed: 16608910]
Reshetnyak YK, Andreev OA, Segala M, Markin VS, Engelman DM. Energetics of peptide (pHLIP)
binding to and folding across a lipid bilayer membrane. Proc Natl Acad Sci U S A. 2008;
105:15340–5. [PubMed: 18829441]
Reshetnyak YK, Segala M, Andreev OA, Engelman DM. A monomeric membrane peptide that lives in
three worlds: in solution, attached to, and inserted across lipid bilayers. Biophys J. 2007; 93:2363–
72. [PubMed: 17557792]
Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth,
survival, and invasion. Cancer Res. 2004; 64:6160–5. [PubMed: 15342400]
Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental
metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66:6699–707.
[PubMed: 16818644]
Samad A, Alam MI, Saxena K. Dendrimers: a class of polymers in the nanotechnology for the delivery
of active pharmaceuticals. Curr Pharm Des. 2009; 15:2958–69. [PubMed: 19754372]
Schornack PA, Gillies RJ. Contributions of cell metabolism and H+ diffusion to the acidic pH of
tumors. Neoplasia. 2003; 5:135–45. [PubMed: 12659686]
Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using
ultrasound to control the release of drugs from liposomes. Chem Phys Lipids. 2009; 162:1–16.
[PubMed: 19703435]
Semalty A, Semalty M, Rawat BS, Singh D, Rawat MS. Pharmacosomes: the lipid-based new drug
delivery system. Expert Opin Drug Deliv. 2009; 6:599–612. [PubMed: 19519287]
Sennoune SR, Luo D, Martinez-Zaguilan R. Plasmalemmal vacuolar-type H+-ATPase in cancer
biology. Cell Biochem Biophys. 2004; 40:185–206. [PubMed: 15054222]
Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by
alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys
Acta. 1999; 1462:55–70. [PubMed: 10590302]
Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. Peptide
radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med. 2001; 28:1555–65. [PubMed:
11685500]
Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet
Oncol. 2001; 2:698–704. [PubMed: 11902541]
Sun H, Nikolovska-Coleska Z, Yang CY, Qian D, Lu J, Qiu S, Bai L, Peng Y, Cai Q, Wang S. Design
of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res. 2008; 41:1264–77.
[PubMed: 18937395]
Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res.
1989; 49:4373–84. [PubMed: 2545340]
Tekade RK, Kumar PV, Jain NK. Dendrimers in Oncology: An Expanding Horizon. Chem Rev. 2009
Thevenin D, An M, Engelman DM. pHLIP-mediated translocation of membrane-impermeable
molecules into cells. Chem Biol. 2009; 16:754–62. [PubMed: 19635412]
Thoren PE, Persson D, Karlsson M, Norden B. The antennapedia peptide penetratin translocates across
lipid bilayers - the first direct observation. FEBS Lett. 2000; 482:265–8. [PubMed: 11024473]
Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell
motility and cancer metastasis. Cancer Sci. 2007; 98:1536–9. [PubMed: 17645779]
Van den Berg B, Clemons WM Jr, Collinson I, Modis Y, Hartmann E, Harrison SC, Rapoport TA. Xray structure of a protein-conducting channel. Nature. 2004; 427:36–44. [PubMed: 14661030]

Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 18

Author Manuscript
Author Manuscript
Author Manuscript

Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic
microenvironment of human tumors: a review. Cancer Res. 1989; 49:6449–65. [PubMed:
2684393]
Vavere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, Engelman DM,
Reshetnyak YK, Lewis JS. A novel technology for the imaging of acidic prostate tumors by
positron emission tomography. Cancer Res. 2009; 69:4510–6. [PubMed: 19417132]
Vives E, Richard JP, Rispal C, Lebleu B. TAT peptide internalization: seeking the mechanism of
entry. Curr Protein Pept Sci. 2003; 4:125–32. [PubMed: 12678851]
Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z. Cell
permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells.
Cancer Res. 2000; 60:1498–502. [PubMed: 10749111]
Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927; 8:519–
530. [PubMed: 19872213]
Wehland J, Osborn M, Weber K. Phalloidin-induced actin polymerization in the cytoplasm of cultured
cells interferes with cell locomotion and growth. Proc Natl Acad Sci U S A. 1977; 74:5613–7.
[PubMed: 341163]
Wei LY, Roepe PD. Low external pH and osmotic shock increase the expression of human MDR
protein. Biochemistry. 1994; 33:7229–38. [PubMed: 7911681]
White SH, von Heijne G. The machinery of membrane protein assembly. Curr Opin Struct Biol. 2004;
14:397–404. [PubMed: 15313232]
Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of
apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during
colorectal carcinogenesis. Oncogene. 1999; 18:3199–204. [PubMed: 10359525]
Wimley WC, White SH. Determining the membrane topology of peptides by fluorescence quenching.
Biochemistry. 2000; 39:161–70. [PubMed: 10625491]
Xiong ZG, Pignataro G, Li M, Chang SY, Simon RP. Acid-sensing ion channels (ASICs) as
pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol. 2008; 8:25–32.
[PubMed: 17945532]
Yoo J, Cui Q. Does arginine remain protonated in the lipid membrane? Insights from microscopic pKa
calculations. Biophys J. 2008; 94:L61–3. [PubMed: 18199662]
Yuan J, Glazer PM. Mutagenesis induced by the tumor microenvironment. Mutat Res. 1998; 400:439–
46. [PubMed: 9685702]
Zoonens M, Reshetnyak YK, Engelman DM. Bilayer interactions of pHLIP, a peptide that can deliver
drugs and target tumors. Biophys J. 2008; 95:225–35. [PubMed: 18359793]

Author Manuscript
Mol Membr Biol. Author manuscript; available in PMC 2015 December 25.

Andreev et al.

Page 19

Author Manuscript

Figure 1.

The sequence of pHLIP peptide.
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Figure 2.

The three major states of pHLIP at a concentration of < 30 μg/mL are illustrated:
unstructured and soluble in water at pH >7 (state I), unstructured and bound to the surface of
a lipid bilayer at the same pH and at a lipid:peptide molar ratio > 100 (state II), and inserted
across the bilayer as an α-helix at low pH (state III). The Figure is taken from (Reshetnyak
et al., 2007).
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Figure 3.
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A schematic representation of the dual delivery capabilities of pHLIP is shown: a) tethering
of cargo molecules to the surface of cells with low extracellular pH and b) translocation of
cell-impermeable polar cargo molecules across the membrane lipid bilayer. State I
corresponds to the peptide in solution at normal and basic pHs. By addition of vesicles, the
unstructured peptide is adsorbed on the membrane surface, raising the local concentration
(State II). A drop of pH leads to the protonation of Asp residues, increasing peptide
hydrophobicity, and resulting in the insertion and formation of a transmembrane alpha-helix
(State III). Lipids interacting with the peptide directly are marked with blue head groups,
lipids influenced by the interaction but not interacting with the peptide directly have cyan
head groups, and lipids that are not involved in the interaction with pHLIP have yellow head
groups. The reprinted from (Andreev et al., 2009) (http://chemistrytoday.teknoscienze.com/).
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